• RNA Pol II Inhibition Triggers Apoptosis via Active Signalin

  2026-05-06

  Harper et al. (2025) reveal that inhibition of RNA polymerase II (Pol II) induces apoptosis through an active, regulated pathway, not merely by loss of transcription. This work redefines mechanistic models for cell death in cancer research, with significant implications for targeting apoptotic signaling.

• Structural Flexibility of Cyclosporin Variants and Mitochond

  2026-05-06

  This study systematically compares cyclosporin B–E variants, revealing how backbone rigidity affects their ability to inhibit the mitochondrial permeability transition pore (MPTP). The findings clarify why Cyclosporin A uniquely combines membrane activity and immunosuppressive function, guiding future research on peptide-based mitochondrial modulators.

• DMXAA (Vadimezan): Precision Tools for Tumor Vasculature and

  2026-05-05

  Explore how DMXAA (Vadimezan) drives advanced cancer biology research through selective vascular disruption, endothelial apoptosis, and unique modulation of the STING-JAK1 axis. This article reveals new experimental insights and practical considerations for DMXAA applications.

• Anti Reverse Cap Analog for Enhanced Synthetic mRNA Capping

  2026-05-05

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, delivers orientation-specific capping that doubles translational efficiency in synthetic mRNA applications. Discover how optimized protocols and troubleshooting strategies with ARCA, powered by APExBIO, drive next-generation mRNA therapeutics and gene editing workflows.

• Anti Reverse Cap Analog (ARCA): Driving hiPSC-to-OL mRNA Inn

  2026-05-04

  Discover how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G empowers high-fidelity mRNA synthesis for hiPSC differentiation into oligodendrocytes. This article reveals protocol-level insights, unique mechanistic advantages, and translational applications of ARCA distinct from existing guides.

• E-64 and Lysoptosis: Defining Cysteine Protease Inhibition i

  2026-05-04

  Explore how E-64, a potent L-trans-epoxysuccinyl peptide, uniquely enables dissection of lysosome-dependent cell death (lysoptosis) in advanced research. This article integrates recent mechanistic insights into cysteine protease inhibition for deeper, more precise experimental design.

• Gramine: Precision Ferroptosis Induction in Cancer Biology R

  2026-05-03

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) is uniquely positioned as a rigorously validated ferroptosis inducer, enabling targeted interrogation of the CUL3–MTDH ubiquitination axis in triple-negative breast cancer research. This article outlines optimized workflows, advanced applications, and troubleshooting insights for leveraging APExBIO’s high-purity Gramine in translational oncology assays.

• Inonotus obliquus Polysaccharides Suppress RA via NF-κB/NLRP

  2026-05-02

  This study integrates network pharmacology and in vivo/in vitro validation to show that Inonotus obliquus polysaccharides (IOP) inhibit key inflammatory pathways in rheumatoid arthritis (RA). The findings clarify IOP's mechanism—suppression of NF-κB and NLRP3 inflammasome activation—highlighting its therapeutic potential and contributing a robust workflow for future immunomodulatory research.

• Branched Endosomal Disruptor Lipids Advance mRNA Delivery Ef

  2026-05-01

  The reference study presents a new class of branched endosomal disruptor (BEND) lipids that significantly enhance mRNA and CRISPR-Cas9 RNP delivery to liver and T cells by improving endosomal escape. These findings provide a rational basis for designing more effective ionizable lipids in nanoparticle formulations, directly addressing persistent bottlenecks in nucleic acid therapeutics.

• FASN Inhibition Primes Cancer Cells for BCL-2-Targeted Apopt

  2026-05-01

  This study establishes that inhibiting fatty acid synthase (FASN) increases mitochondrial apoptotic priming in cancer cells, making them more susceptible to apoptosis induced by BCL-2 family inhibitors such as ABT-263 (Navitoclax). These findings provide a mechanistic basis for combining FASN inhibitors with BH3 mimetic agents to enhance antitumor efficacy, especially in breast cancer models.

• Oligo (dT) 25 Beads: Mechanistic Insights for High-Fidelity

  2026-04-30

  Explore the mechanistic underpinnings and advanced protocol optimization of Oligo (dT) 25 Beads for eukaryotic mRNA isolation. This in-depth guide reveals how superparamagnetic beads revolutionize assay reliability in transcriptomics and functional genomics.

• Caspase-3 Colorimetric Assay Kit: Reliable Apoptosis Detecti

  2026-04-30

  The Caspase-3 Colorimetric Assay Kit enables sensitive, quantitative measurement of DEVD-dependent caspase-3 activity, facilitating robust apoptosis assays in cell biology and neurodegenerative disease models. It is best suited for research applications requiring rapid, colorimetric quantification of caspase-3, but should not be used for direct in vivo analysis or when high-throughput multiplexing is required.

• Silybin A in Precision Hepatology: Chemistry, Protocols, and

  2026-04-29

  Explore Silybin A, the bioactive heart of Silymarin, as a precision hepatoprotective agent. This article uniquely integrates advanced chemical insights and assay guidance to elevate metabolic and liver disease research.

• FOXO3-Mediated Dual Metabolic Inhibition in HCC: Mechanistic

  2026-04-29

  This article reviews the recent discovery that FOXO3 functions as a suppressor of both glycolysis and glutaminolysis in hepatocellular carcinoma (HCC) via direct repression of YAP transcription. The findings provide compelling evidence for targeting the FOXO3/YAP axis as a dual metabolic intervention strategy in HCC, with implications for metabolic-based therapeutic development.

• Ceruletide in Pancreatic Fibrosis Models: Mechanistic Precis

  2026-04-28

  Explore how Ceruletide, a synthetic CCK analog, advances pancreatic fibrosis and gastrointestinal physiology research. This in-depth analysis uncovers mechanistic nuances, protocol optimization, and strategic insights not covered by other resources.

16051 records 1/1071 page Next 12345 下5页 Last page